A multi-stakeholder collaborative approach to awareness, education and support needed in the haemophilia gene therapy patient journey – a report on insights from a European patient advisory board

1. Srivastava A, Santagostino E, Dougall A, et al.; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26(S6): 1-158. doi: 10.1111/hae.14046. Srivastava A Santagostino E Dougall A .; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition . Haemophilia 2020 ; 26 (S6): 1 - 158 . doi: 10.1111/hae.14046 . Open DOISearch in Google Scholar

2. Manco-Johnson MJ, Michael Soucie J, Cox J. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia 1999 to 2010: a surveillance project. Blood 2017; 129(17): 2368-2374. doi: 10.1182/blood-2016-02-683169. Manco-Johnson MJ Michael Soucie J Cox J. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia 1999 to 2010: a surveillance project . Blood 2017 ; 129 ( 17 ): 2368 - 2374 . doi: 10.1182/blood-2016-02-683169 . Open DOISearch in Google Scholar

3. O’Hara S, Castro FA, Black J, et al. Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis. Haemophilia 2021; 27(1): 113-119. doi: 10.1111/hae.14171. O’Hara S Castro FA Black J . Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis . Haemophilia 2021 ; 27 ( 1 ): 113 - 119 . doi: 10.1111/hae.14171 . Open DOISearch in Google Scholar

4. Brod M, Bushnell DM, Neergaard JS, Waldman LT, Busk AK. Understanding treatment burden in hemophilia: development and validation of the Hemophilia Treatment Experience Measure (Hemo-TEM). J Patient Rep Outcomes 2023; 7: 17. doi: 10.1186/s41687-023-00550-6. Brod M Bushnell DM Neergaard JS Waldman LT Busk AK. Understanding treatment burden in hemophilia: development and validation of the Hemophilia Treatment Experience Measure (Hemo-TEM) . J Patient Rep Outcomes 2023 ; 7 : 17 . doi: 10.1186/s41687-023-00550-6 . Open DOISearch in Google Scholar

5. Chowdary P. Extended half-life recombinant products in haemophilia clinical practice – Expectations, opportunities and challenges. Thromb Res 2020; 196: 609-617. doi: 10.1016/j.thromres.2019.12.012. Chowdary P. Extended half-life recombinant products in haemophilia clinical practice – Expectations, opportunities and challenges . Thromb Res 2020 ; 196 : 609 - 617 . doi: 10.1016/j.thromres.2019.12.012 . Open DOISearch in Google Scholar

6. Ellsworth P. Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates? Hematology Am Soc Hematol Educ Program 2021; 2021(1): 219-225. doi: 10.1182/hematology.2021000253. Ellsworth P. Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates? Hematology Am Soc Hematol Educ Program 2021 ; 2021 ( 1 ): 219 - 225 . doi: 10.1182/hematology.2021000253 . Open DOISearch in Google Scholar

7. Young G. Nonfactor therapies for hemophilia. Hemasphere 2023; 7(6): e911. doi: 10.1097/HS9.0000000000000911. Young G. Nonfactor therapies for hemophilia . Hemasphere 2023 ; 7 ( 6 ) : e911. doi: 10.1097/HS9.0000000000000911 . Open DOISearch in Google Scholar

8. Chowdary P. Nonfactor therapies: New approaches to prophylactic treatment of haemophilia. Hamostaseologie 2021; 41(4): 247–256. doi: 10.1055/a-1424-7900. Chowdary P. Nonfactor therapies: New approaches to prophylactic treatment of haemophilia . Hamostaseologie 2021 ; 41 ( 4 ): 247 – 256 . doi: 10.1055/a-1424-7900 . Open DOISearch in Google Scholar

9. Wells JR, Gater A, Marshall C, Tritton T, Vashi P, Kessabi S. Exploring the impact of infusion frequency in hemophilia A: exit interviews with patients participating in BAY 94–9027 extension studies (PROTECT VIII). Patient 2019;12(6):611–619. doi: 10.1007/s40271-019-00374-x. Wells JR Gater A Marshall C Tritton T Vashi P Kessabi S. Exploring the impact of infusion frequency in hemophilia A: exit interviews with patients participating in BAY 94–9027 extension studies (PROTECT VIII) . Patient 2019 ; 12 ( 6 ): 611 – 619 . doi: 10.1007/s40271-019-00374-x . Open DOISearch in Google Scholar

10. Cantore A, Naldini L. WFH State-of-the-art paper 2020: In vivo lentiviral vector gene therapy for haemophilia. Haemophilia 2021; 27(S3): 122-125. doi: 10.1111/hae.14056. Cantore A Naldini L. WFH State-of-the-art paper 2020: In vivo lentiviral vector gene therapy for haemophilia . Haemophilia 2021 ; 27 (S3): 122 - 125 . doi: 10.1111/hae.14056 . Open DOISearch in Google Scholar

11. Rodríguez-Merchán EC, De Pablo-Moreno JA, Liras A. Gene therapy in hemophilia: recent advances. Int J Mol Sci 2021; 22: 7647. doi: 10.3390/ijms22147647. Rodríguez-Merchán EC De Pablo-Moreno JA Liras A. Gene therapy in hemophilia: recent advances . Int J Mol Sci 2021 ; 22 : 7647 . doi: 10.3390/ijms22147647 . Open DOISearch in Google Scholar

12. Wang M, Negrier C, Diessler F, Goodman C, Skinner MW. The haemophilia gene therapy patient journey questions and answers for shared decision-making. Patient Prefer Adherence 2022; 16: 1439-1447. doi: 10.2147/PPA.S355627. Wang M Negrier C Diessler F Goodman C Skinner MW. The haemophilia gene therapy patient journey questions and answers for shared decision-making . Patient Prefer Adherence 2022 ; 16 : 1439 - 1447 . doi: 10.2147/PPA.S355627 . Open DOISearch in Google Scholar

13. Le Quellec S, Breederveld D, Coppens M, Pinachyan K. The paradigm shift of gene therapy for haemophilia: impact on the patient journey. ESGCT 29th Annual Congress in collaboration with BSGCT Edinburgh, UK, 11-14 October 2022 (P129). Le Quellec S Breederveld D Coppens M Pinachyan K. The paradigm shift of gene therapy for haemophilia: impact on the patient journey . ESGCT 29th Annual Congress in collaboration with BSGCT Edinburgh, UK , 11-14 October 2022 (P129). Search in Google Scholar

14. Valentino L, Blanchette V, Negrier C, O’Mahony B, Bias V, Sannié T, Skinner MW. Personalising haemophilia management with shared decision making. J Haem Pract 2021; 8(1): 69-79. doi: 10.17225/jhp00178. Valentino L Blanchette V Negrier C O’Mahony B Bias V Sannié T Skinner MW. Personalising haemophilia management with shared decision making . J Haem Pract 2021 ; 8 ( 1 ): 69 - 79 . doi: 10.17225/jhp00178 . Open DOISearch in Google Scholar

15. Miesbach W, O’Mahony B, Key NS, Makris M. How to discuss gene therapy for haemophilia? A patient and physician perspective. Haemophilia 2019; 25(4): 545-557. doi: 10.1111/hae.13769. Miesbach W O’Mahony B Key NS Makris M. How to discuss gene therapy for haemophilia? A patient and physician perspective . Haemophilia 2019 ; 25 ( 4 ): 545 - 557 . doi: 10.1111/hae.13769 . Open DOISearch in Google Scholar

16. Woollard L, Gorman R, Rosenfelt DJ. Improving patient informed consent for haemophilia gene therapy: the case for change. Ther Adv Rare Dis 2021; 2: 1-16. doi: 10.1177/26330040211047244. Woollard L Gorman R Rosenfelt DJ. Improving patient informed consent for haemophilia gene therapy: the case for change . Ther Adv Rare Dis 2021 ; 2 : 1 - 16 . doi: 10.1177/26330040211047244 . Open DOISearch in Google Scholar

17. Miesbach W, Garcia Barcenilla S, Golan G, Lobet S. Implications of haemophilia gene therapy for the changing role of the multidisciplinary team. Haemophilia 2022; 28(1): e12-e14. doi: 10.1111/hae.14440. Miesbach W Garcia Barcenilla S Golan G Lobet S. Implications of haemophilia gene therapy for the changing role of the multidisciplinary team . Haemophilia 2022 ; 28 ( 1 ) : e12-e14. doi: 10.1111/hae.14440 . Open DOISearch in Google Scholar

18. Limjoco J, Calatroni A, Aristizabal P, Thornburg CD. Gene therapy preferences and informed decision-making. Results from a National Hemophilia Foundation Community Voices in Research survey. Haemophilia 2023; 29(1): 50-60. doi: 10.1111/hae.14706. Limjoco J Calatroni A Aristizabal P Thornburg CD. Gene therapy preferences and informed decision-making. Results from a National Hemophilia Foundation Community Voices in Research survey . Haemophilia 2023 ; 29 ( 1 ): 50 - 60 . doi: 10.1111/hae.14706 . Open DOISearch in Google Scholar

19. Fletcher S, Jenner K, Khair K. Shared decision-making for gene therapy in haemophilia care. J Haem Pract 2023; 10(1): 62-67. doi: 10.2478/jhp-2023-0009. Fletcher S Jenner K Khair K. Shared decision-making for gene therapy in haemophilia care . J Haem Pract 2023 ; 10 ( 1 ): 62 - 67 . doi: 10.2478/jhp-2023-0009 . Open DOISearch in Google Scholar

20. Fletcher S, Jenner K, Pembroke L, Holland M, Khair K. The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, The Exigency Study. Orphanet J Rare Dis 2022; 17(1): 155. doi: 10.1186/s13023-022-02256-2. Fletcher S Jenner K Pembroke L Holland M Khair K. The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, The Exigency Study . Orphanet J Rare Dis 2022 ; 17 ( 1 ): 155 . doi: 10.1186/s13023-022-02256-2 . Open DOISearch in Google Scholar

21. Noone D, Astermark J, O’Mahony B, et al. The journey of gene therapy in haemophilia – putting the patient at the centre of the hub and spoke model. J Haem Pract 2022; 9(1): 156-166. doi: 10.2478/jhp-2022-0021. Noone D Astermark J O’Mahony B . The journey of gene therapy in haemophilia – putting the patient at the centre of the hub and spoke model . J Haem Pract 2022 ; 9 ( 1 ): 156 - 166 . doi: 10.2478/jhp-2022-0021 . Open DOISearch in Google Scholar

22. Rayment R, Chalmers E, Forsyth K, et al.; British Society for Haematology. Guidelines on the use of prophylactic factor replacement for children and adults with haemophilia A and B. Br J Haem 2020; 190(5): 684-695. doi: 10.1111/bjh.16704. Rayment R Chalmers E Forsyth K British Society for Haematology .;. Guidelines on the use of prophylactic factor replacement for children and adults with haemophilia A and B . Br J Haem 2020 ; 190 ( 5 ): 684 - 695 . doi: 10.1111/bjh.16704 . Open DOISearch in Google Scholar

23. Limjoco J, Calatroni A, Aristizabal P, Thornburg CD. Gene therapy preferences and informed decision-making: Results from a National Hemophilia Foundation Community Voices in Research survey. Haemophilia 2023; 19(1): 51-60. doi: 10.1111/hae.14706. Limjoco J Calatroni A Aristizabal P Thornburg CD. Gene therapy preferences and informed decision-making: Results from a National Hemophilia Foundation Community Voices in Research survey . Haemophilia 2023 ; 19 ( 1 ): 51 - 60 . doi: 10.1111/hae.14706 . Open DOISearch in Google Scholar

24. Pierce GF, Iorio A. Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes. Haemophilia 2018; 24(S6): 60-67. doi: 10.1111/hae.13489. Pierce GF Iorio A. Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes . Haemophilia 2018 ; 24 (S6): 60 - 67 . doi: 10.1111/hae.13489 . Open DOISearch in Google Scholar

25. Yamaguti-Hayakawa GG, Ozelo MC. Gene therapy for haemophilia: looking beyond factor expression. Exp Biol Med (Maywood) 2022; 247(24): 2223-2232. doi: 10.1177/15353702221147565. Yamaguti-Hayakawa GG Ozelo MC. Gene therapy for haemophilia: looking beyond factor expression . Exp Biol Med (Maywood) 2022 ; 247 ( 24 ): 2223 - 2232 . doi: 10.1177/15353702221147565 . Open DOISearch in Google Scholar

26. Krumb E, Hermans C. Living with a “hemophilia-free mind” – The new ambition of haemophilia care? Res Pract Thromb Haemost 2021; 5(5): e12567. doi: 10.1002/rth2.12567. Krumb E Hermans C. Living with a “hemophilia-free mind” – The new ambition of haemophilia care? Res Pract Thromb Haemost 2021 ; 5 ( 5 ) : e12567. doi: 10.1002/rth2.12567 . Open DOISearch in Google Scholar

27. Hermans C, Gruel Y, Frenzel L, Krumb E. How to translate and implement the current science of gene therapy into haemophilia care? Ther Adv Hematol 2023; 14: 20406207221145627. doi: 10.1177/20406207221145627. Hermans C Gruel Y Frenzel L Krumb E. How to translate and implement the current science of gene therapy into haemophilia care? Ther Adv Hematol 2023 ; 14 : 20406207221145627. doi: 10.1177/20406207221145627 . Open DOISearch in Google Scholar

28. Boyce S, Fletcher S, Jones A, et al. Educational needs of patients, families, and healthcare professionals to support the patient journey in haemophilia gene therapy. Orphanet J Rare Dis 2023; 18: 366. doi: 10.1186/s13023-023-02977-y. Boyce S Fletcher S Jones A . Educational needs of patients, families, and healthcare professionals to support the patient journey in haemophilia gene therapy . Orphanet J Rare Dis 2023 ; 18 : 366 . doi: 10.1186/s13023-023-02977-y . Open DOISearch in Google Scholar

29. Pierce GF, Coffin D, Members of the WFH Gene Therapy Round Table Program Committee and Organizing Committee. The 1st WFH Gene Therapy Round Table: Understanding the landscape and challenges of gene therapy for haemophilia around the world. Haemophilia 2019; 25(2): 189-194. doi: 10.1111/hae.13673. Pierce GF Coffin D Members of the WFH Gene Therapy Round Table Program Committee and Organizing Committee . The 1st WFH Gene Therapy Round Table: Understanding the landscape and challenges of gene therapy for haemophilia around the world . Haemophilia 2019 ; 25 ( 2 ): 189 - 194 . doi: 10.1111/hae.13673 . Open DOISearch in Google Scholar